Manual therapy improves fibromyalgia symptoms by downregulating SIK1
RNA-seq (gene expression) · human · 12 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 12 samples: 12 samples, each with a distinct title — no replicated groupsGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Manual Therapy Improves Fibromyalgia Symptoms by Downregulating SIK1International journal of molecular sciences · 2024
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE274134_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1145016 and SRA study SRP524568. Searching any of these in the dataset finder brings you back here.
Any grouping that defines a comparison lives in the sample characteristics, which GEO records separately from the titles.
How we read this: Read from 12 sample titles: 12 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8444011 Total RNA from PBMC of FM1 patient post MT treatment
- GSM8444012 Total RNA from PBMC of FM1 patient pre MT treatment
- GSM8444013 Total RNA from PBMC of FM2 patient post MT treatment
- GSM8444014 Total RNA from PBMC of FM2 patient pre MT treatment
- GSM8444015 Total RNA from PBMC of FM3 patient post MT treatment
- GSM8444016 Total RNA from PBMC of FM3 patient pre MT treatment
- GSM8444017 Total RNA from PBMC of FM4 patient post MT treatment
- GSM8444018 Total RNA from PBMC of FM4 patient pre MT treatment
- GSM8444019 Total RNA from PBMC of FM5 patient post MT treatment
- GSM8444020 Total RNA from PBMC of FM5 patient pre MT treatment
- GSM8444021 Total RNA from PBMC of FM6 patient post MT treatment
- GSM8444022 Total RNA from PBMC of FM6 patient pre MT treatment
- GSE271137 Characterization of Chemoresistant Cell Populations Improves Risk Stratification and Therapy Prediction in Pediatric AML 75 samples shares improves, therapy
- GSE270894 Molecular Characterization of Chemoresistant Cell Populations Improves Risk Stratification and Therapy Response Prediction in Pediatric AML [pAML Patients scRNA-seq] 20 samples shares improves, therapy
- GSE217387 Stimulation of tumor infiltrating B-cells improves ex-vivo TIL expansion for melanoma sample immunotherapy I 20 samples shares improves, therapy
- GSE308825 Molecular Characterization of Chemoresistant Cell Populations Improves Risk Stratification and Therapy Response Prediction in Pediatric AML [Treatment_Study_RNA-seq] 17 samples shares improves, therapy
- GSE271134 Molecular Characterization of Chemoresistant Cell Populations Improves Risk Stratification and Therapy Response Prediction in Pediatric AML [pAML PDX Bulk RNA-seq] 14 samples shares improves, therapy
- GSE270892 Molecular Characterization of Chemoresistant Cell Populations Improves Risk Stratification and Therapy Response Prediction in Pediatric AML [pAML Patients Bulk RNA-seq] 12 samples shares improves, therapy
- GSE271136 Molecular Characterization of Chemoresistant Cell Populations Improves Risk Stratification and Therapy Response Prediction in Pediatric AML [pAML PDX scRNA-seq] 12 samples shares improves, therapy
- GSE210156 Gut microbial metabolite butyrate improves anticancer therapy by regulating intracellular calcium homeostasis 9 samples shares improves, therapy
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.